Comparison to previously published, similar cohorts
death, neoplasms, thrombocytopenia, PET-MF, PPV-MF, PMF
NEOPLASMS, THROMBOCYTOPENIA, DISORDERS, ADVERSE EVENT, BLOOD AND LYMPHATIC SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS
The JAKoMo cohort is the first large, “real-world” cohort to be reported following RUX approval in the EU. It comprises a broader range of patients than enrolled in the COMFORT and JUMP trials. Table Patients in the JAKoMo trial were enrolled mainly through office-based hematologists/oncologists (88% of patients), much fewer at community hospitals (9% of patients), and a minority at academic centers (2% of patients). Individual centers enrolled between one and 27 patients. Mean study duration of all patients was 20.2 months, with similar durations among patients with PMF, PPV-MF, and PET-MF. At the time of analysis, 54.3% of all patients had dropped out of the study, the major reasons being death, AEs, and deterioration of general health. 79 patients suffered from an adverse event which led to treatment termination. Main system organ classes for AEs leading to treatment discontinuation and drop out of the study were: general disorders and administration site conditions (18 patients), blood and lymphatic system disorders (17 patients with e.g. thrombocytopenia in 9 patients), gastrointestinal disorders (12 patients), and neoplasms (benign, malignant and unspecified) (17 patients). Allogenic stem cell transplantation was performed in 5 patients. The present analysis focuses exclusively on the JAKi-naïve patients (Arm A).